J&J says its single dose protects against breakthrough COVID-19 for up to 6 months

Reuters2022-01-07

Jan 6 (Reuters) - Johnson & Johnson said on Thursday that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.

The study, sponsored by the vaccine developer, was conducted between Jan. 1 and Sept. 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.

J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna.

No waning of protection was found for ICU admissions for all the three vaccines, J&J said.

The company said the study was carried out by collecting claims and laboratory data covering 168 million people.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • LimLK
    2022-01-07
    LimLK
    Hope this Covid-19 and whatever variants are over soon! 
  • ping23
    2022-01-07
    ping23
    pls like
  • ping23
    2022-01-07
    ping23
    pls like
  • ivy888
    2022-01-07
    ivy888
    Like 
  • Kaden0204
    2022-01-07
    Kaden0204
    Good
  • Ken3888
    2022-01-07
    Ken3888
    K
Leave a comment
8